Sign in to baba News

The Desk, the news read to you every hour, is part of News Plus.

or use an email code

By continuing you agree to the terms and privacy policy.

Keep the whole picture

News Plus opens the cross-newsroom layer: who covered a story, who didn’t, and how each one worded it.

  • Unlimited follows
  • Alerts for what you follow (in the app)
  • Story alerts (in the app)
  • Hide read stories
  • The daily brief by email
  • Headlines side by side
  • Who reported first
  • Every newsroom clip, from every platform
  • The whole archive
  • Your reading diet
  • Duki without the daily limit
  • The Desk: the news, spoken every hour
  • Catch Me Up, and what changed since you read it
  • The Live Terminal

Eligible new subscribers get 7 days free, then $34.99 each year. Renews automatically until cancelled. Cancel any time in your account. Subscription terms.

Your subscription also unlocks the app.

Download on theApp StoreGet it onGoogle Play

Sign in to baba News

One account across the web, iPhone and Android — your subscription follows it.

or use an email code

By continuing you agree to the terms and privacy policy.

Welcome, one more step

News Plus opens the cross-newsroom layer: who covered a story, who didn’t, and how each one worded it.

  • Unlimited follows
  • Alerts for what you follow (in the app)
  • Story alerts (in the app)
  • Hide read stories
  • The daily brief by email
  • Headlines side by side
  • Who reported first
  • Every newsroom clip, from every platform
  • The whole archive
  • Your reading diet
  • Duki without the daily limit
  • The Desk: the news, spoken every hour
  • Catch Me Up, and what changed since you read it
  • The Live Terminal

Eligible new subscribers get 7 days free, then $34.99 each year. Renews automatically until cancelled. Cancel any time in your account. Subscription terms.

Your subscription also unlocks the app.

Download on theApp StoreGet it onGoogle Play

Search stories

Type at least two characters. Results come from every newsroom baba reads.

↑↓ to move · ↵ to open · esc to close

Sign in to baba News

Sign in to keep asking. News Plus removes the daily limit.

or use an email code

By continuing you agree to the terms and privacy policy.

Keep the whole picture

News Plus opens the cross-newsroom layer: who covered a story, who didn’t, and how each one worded it.

  • Unlimited follows
  • Alerts for what you follow (in the app)
  • Story alerts (in the app)
  • Hide read stories
  • The daily brief by email
  • Headlines side by side
  • Who reported first
  • Every newsroom clip, from every platform
  • The whole archive
  • Your reading diet
  • Duki without the daily limit
  • The Desk: the news, spoken every hour
  • Catch Me Up, and what changed since you read it
  • The Live Terminal

Eligible new subscribers get 7 days free, then $34.99 each year. Renews automatically until cancelled. Cancel any time in your account. Subscription terms.

Your subscription also unlocks the app.

Download on theApp StoreGet it onGoogle Play
YnetnewsHealth

Pharma Giants Spar Over Weight-Loss Drugs at Diabetes Conference

By Oren Rice

Summarized from Ynetnews by baba

CenterCharged tone

English · Sole source

OriginalBattle of the weight-loss shots: Which one works best?

The story in 5 lines · by baba

  • Novo Nordisk and Eli Lilly presented conflicting data on weight-loss drugs at a diabetes conference.
  • Eli Lilly's Mounjaro showed greater weight loss than Novo Nordisk's Wegovy in direct trials.
  • Novo Nordisk claimed Ozempic offered better heart protection for diabetic patients.
  • Direct comparative trials for cardiovascular protection between the leading drugs are still lacking.
  • Weight-loss injections are not state-funded for adults in Israel and pills are often unaffordable.

Ynetnews publishes in English. The key points are summarized above. Read Ynetnews’s full report at the source below.

Read the original at Ynetnews
YnetnewsCentre · Rishon LeZion

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

By continuing you agree to the terms and privacy policy.

You’ve used your five follows

News Plus follows as many newsrooms, topics and people as you like.

  • Unlimited follows
  • Alerts for what you follow (in the app)
  • Story alerts (in the app)
  • Hide read stories
  • The daily brief by email
  • Headlines side by side
  • Who reported first
  • Every newsroom clip, from every platform
  • The whole archive
  • Your reading diet
  • Duki without the daily limit
  • The Desk: the news, spoken every hour
  • Catch Me Up, and what changed since you read it
  • The Live Terminal
See News Plus
HealthTopic

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

By continuing you agree to the terms and privacy policy.

You’ve used your five follows

News Plus follows as many newsrooms, topics and people as you like.

  • Unlimited follows
  • Alerts for what you follow (in the app)
  • Story alerts (in the app)
  • Hide read stories
  • The daily brief by email
  • Headlines side by side
  • Who reported first
  • Every newsroom clip, from every platform
  • The whole archive
  • Your reading diet
  • Duki without the daily limit
  • The Desk: the news, spoken every hour
  • Catch Me Up, and what changed since you read it
  • The Live Terminal
See News Plus

Mentioned

Prof. John WildingDr. Michael RadinRachel BatterhamNovo NordiskEli LillyEuropean Association for the Study of DiabetesMass General BrighamHarvardMilanItalyUnited StatesGermany
Full coverage · 2 outlets
100% centerFirst: Ynet · Sep 29

The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.

Center 2
Open the live terminal